Merck (MRK), Syndax Pharma to Collaborate on NSCLC, Melanoma Treatment Trial
Tweet Send to a Friend
Merck (NYSE: MRK) and Syndax Pharmaceuticals announced that they have entered into a clinical trial collaboration to evaluate the safety ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE